TNFSF13B and myasthenia gravis: Figure 1A–D presents differences in BAFF levels depending on the serological status of non-T-MG patients (1A), presence of thymoma (1B), treatment with prednisone within last three months in T-MG vs. non-T-MG patients (1C) and treatment with CS in the past (1D).